A Prospective Study of Circulating C-Reactive Protein, Interleukin-6, and Tumor Necrosis Factor α Receptor 2 Levels and Risk of Ovarian Cancer

Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness

(2013) E. M. Poole et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study

(2011) A. T. Toriola et al.   ANNALS OF ONCOLOGY

Circulating Inflammation Markers and Risk of Epithelial Ovarian Cancer

(2011) T. V. Clendenen et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment

(2011) H. Kulbe et al.   CANCER RESEARCH

Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles

(2010) Giampiero Capobianco et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy)

(2009) Eva Lundin et al.   CANCER CAUSES & CONTROL

Serum C-reactive protein in the differential diagnosis of ovarian masses

(2009) Katrin Hefler-Frischmuth et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer

(2009) Kristine H. Allin et al.   JOURNAL OF CLINICAL ONCOLOGY

C-reactive protein across the menstrual cycle

(2008) Katherine Wander et al.   AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY

Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis

(2008) Katriina Heikkilä et al.   CANCER CAUSES & CONTROL

Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer

(2008) L. A. Hefler et al.   CLINICAL CANCER RESEARCH

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

(2008)   LANCET